Opens in a new tab

Ter Meer Steinmeister & Partner Patentanwälte mbB v 2seventy bio (CFI, 23 July 2026)

Date23 July 2026
CourtCFI
DivisionBrussels (BE) Local Division
Type of actionApplication RoP262.1 (b)
Case number(s)UPC_CFI_2192/2026
Registry referenceUPC_CFI_2192/2026
PartiesTER MEER STEINMEISTER & PARTNER PATENTANWÄLTE MBB v. (1) 2SEVENTY BIO, INC. / (2) JOHNSON & JOHNSON / (3) JANSSEN BIOTECH, INC. / (4) JANSSEN …

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In an order of 23 July 2026 (UPC_CFI_2192/2026), the judge-rapporteur of the Brussels Local Division dismisses the application by the patent attorney firm Ter Meer Steinmeister & Partner for access to 2seventy bio’s statement of claim on claim construction (UPC_CFI_29/2026) and to the defendants’ counterclaims for revocation (UPC_CFI_1934/2026 and UPC_CFI_1940/2026), in the dispute between 2seventy bio and the Johnson & Johnson, Janssen and Legend Biotech companies over EP 3 689 383. The order confirms that, while proceedings are pending, an adviser acting for unidentified clients does not show the specific interest required.

Question

Can a firm obtain access to pleadings in pending proceedings by relying on the interest of unnamed clients and an EPO opposition deadline?

Decision

No. Public access is the rule and restriction the exception (Arts. 10 and 45 UPCA, paragraph 7), and law firms are in principle part of the public (paragraphs 9 and 10). But while proceedings are pending, only a more specific or direct legitimate interest can outweigh the protection of the integrity of the proceedings (paragraphs 12 and 13). The applicant is neither a competitor nor a licensee and identifies no client, product or infringement allegation (paragraph 15). Nicoventures v Juul/NJOY is distinguishable, since access there was granted to an opponent party to pending EPO appeal proceedings (paragraph 16). The opposition deadline of 30 September 2026 does not establish the required interest, as no client instructing an opposition is identified (paragraph 17). The application is dismissed as unfounded.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 10 and 45
Rules of Procedure
Rules 220.2, 220.3, 262.1(b) and 333
Case law cited
Ocado v Autostore, Court of Appeal, 10 April 2024, Nicoventures v Juul/NJOY, Court of Appeal, 25 April 2025 (UPC_CoA_5/2025), Insulet v EOFlow, Court of Appeal, HSF v Insulet/EOFlow, Court of Appeal, 22 December 2025, Gowling v Sumi Agro/Syngenta, Court of Appeal, 24 February 2026, Huawei v Quinn Emanuel Urquhart & Sullivan, Court of Appeal, 29 June 2026

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_2192/2026 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262.1 (b)
Outcome (Dhenne Avocats summary)
La demande d'accès aux écritures de la procédure en cours est rejetée, le cabinet demandeur ne justifiant d'aucun intérêt spécifique ou direct.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 689 383Mentioned in the analysis (role not qualified)
Also mentioned in 2 other decision(s): 2seventy bio v Johnson & Johnson (CFI, UPC_CFI_29/2026, 15 June 2026) · 2seventy bio v Johnson & Johnson (CFI, 8 June 2026)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.